Menu About Vallon Advancing Novel Formulations to Reduce Medication Abuse Menu Company Overview About Us Vallon Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel abuse-deterrent medications for CNS disorders. The Company’s lead investigational product candidate, ADAIR (Abuse-Deterrent Amphetamine Immediate-Release), is a proprietary abuse-deterrent formulation of immediate release (IR) dextroamphetamine in development for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. ADAIR is designed to deter attempts to crush and snort and provides barriers to injection. Leveraging the clinical success of dextroamphetamine, we are developing ADAIR through a streamlined 505(b)(2) U.S. FDA regulatory pathway, which is expected to obviate the need for large Phase 2 and Phase 3 efficacy and safety studies. If approved, ADAIR is expected to be the first abuse-deterrent, immediate-release formulation of dextroamphetamine. Abuse-Deterrent Formulation Technology Our Pipeline Leadership We are Driven by Accomplishment Our leadership includes accomplished biopharmaceutical professionals who have developed and commercialized many of the best-known CNS products of the past two decades. Our team brings extensive experience operating across large pharma, specialty pharma, and start-up environments. Key Accomplishments 5 different billion-dollar products commercialized, including the two best-selling ADHD medications 29 U.S. and international new products developed and/or approved, including 4 different ADHD drugs Management Team David Baker President & CEO Tim Whitaker, M.D. Chief Medical Officer Penny Toren Senior VP, Regulatory Affairs & Project Management Leanne Kelly Chief Financial Officer Board of Directors Ofir Levi, Ph.D. Chairman Joseph Payne Director Richard Ammer, M.D., Ph.D. Director Marella Thorell Director David Baker President & CEO Scientific Advisory Board Stephen V. Faraone, Ph.D. Scientific Advisory Board Jeffrey Newcorn, M.D. Scientific Advisory Board Anthony Rostain, M.D. Scientific Advisory Board Collaborations We Collaborate with Industry Leaders Developing products with disruptive potential requires collaboration. We are working with leading academics, businesses, professional organizations, and patient advocacy groups to advance our mission of bringing novel products to large markets in need. Medice Strategic Marketing Partner in EU Lonza® Formulation + Development CHADD Patient Advocacy Abuse Deterrent Coalition Patient Advocacy APSARD Industry Organization BIO Industry Organization Life Sciences Pennsylvania Industry Organization Sign Up for Updates © 2021 Vallon Pharmaceuticals | Terms of Use | Privacy Policy ADAIR is an investigational new drug product and has not yet been approved by the FDA. All trademarks shown are the property of their respective owners.